Can a pill boost brain blood flow in Alzheimer's? new trial aims to find out
NCT ID NCT07191821
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 29 times
Summary
This phase 2 trial tests whether an experimental drug called XBD173 can improve blood flow in the brains of people with Alzheimer's disease. About 51 participants will take the drug or a placebo for 28 days. Researchers will use MRI scans and blood tests to measure changes in brain blood flow and other markers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NIHR Imperial CRF
London, W12 0HS, United Kingdom
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
XBD173 (an experimental drug taken orally)
What this could lead to
If it works, this could point toward a new way to improve blood flow in the brain for people with Alzheimer's, potentially slowing memory decline.
What could go wrong
This is a small, early-phase trial testing a short-term effect on a biomarker (blood flow), not on memory or daily function. The drug may not show benefit or could have side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.